US · KMDA
Kamada Ltd.
- Sector
- Healthcare · Drug Manufacturers - Specialty & Generic
- Headquarters
- Rehovot 7670402
- Website
- kamada.com
Price · as of 2024-12-31
$8.21
Market cap 501.83M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $55.49 | +575.88% |
| Intrinsic Value(DCF) | $3.23 | -60.66% |
| Graham-Dodd Method(GD) | $5.24 | -36.13% |
| Graham Formula(GF) | $5.17 | -36.98% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | $0.00 | $0.00 | |||
| 2011 | $0.19 | $0.00 | |||
| 2012 | $1.06 | $0.34 | |||
| 2013 | $15.34 | $41.18 | $1.91 | $2.82 | $0.07 |
| 2014 | $3.97 | $120.80 | $0.82 | $0.50 | $0.00 |
| 2015 | $3.95 | $23.73 | $0.21 | $0.45 | $0.00 |
| 2016 | $6.85 | $52.78 | $0.00 | $0.91 | $0.00 |
| 2017 | $5.06 | $30.83 | $4.68 | $3.27 | $7.14 |
| 2018 | $5.76 | $25.44 | $11.84 | $5.56 | $10.54 |
| 2019 | $5.53 | $28.51 | $13.77 | $6.12 | $10.40 |
| 2020 | $6.03 | $34.02 | $1.30 | $5.99 | $4.94 |
| 2021 | $5.36 | $53.88 | $0.12 | $3.02 | $0.65 |
| 2022 | $4.08 | $147.25 | $0.00 | $2.99 | $0.00 |
| 2023 | $5.88 | $72.21 | $0.26 | $5.22 | $3.03 |
| 2024 | $7.20 | $55.49 | $1.65 | $5.24 | $5.17 |
AI valuation
Our deep-learning model estimates Kamada Ltd.'s (KMDA) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $55.49
- Current price
- $8.21
- AI upside
- +575.88%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$3.23
-60.66% upside
Graham-Dodd
$5.24
-36.13% upside
Graham Formula
$5.17
-36.98% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| KMDA | Kamada Ltd. | $8.21 | 501.83M | +576% | -61% | -36% | -37% | 28.63 | 1.60 | 2.57 | 12.47 | 42.95 | 3.25 | 43.47% | 12.46% | 8.99% | 5.74% | 10.30% | 3.98% | 0.04 | 30.38 | 3.73 | 2.06 | -2.42 | 6667.00% | 1293.00% | -250091.00% | 8.90% | 0.96 | 18.93% | 0.00% | 0.00% | 4.96% | 17.29 | 9.41 | 2.15 | 3.15 |
| AUNA | Auna S.A. | $5.34 | 395.39M | +191% | +579% | -79% | +93% | 15.62 | 1.31 | 0.44 | 5.78 | — | -1.64 | 37.18% | 16.08% | 2.51% | 8.43% | 9.59% | 1.68% | 2.55 | 1.46 | 0.88 | 0.67 | 3.81 | -12820.00% | 1447.00% | 3844.00% | 29.83% | 0.34 | 11.60% | 0.06% | 0.90% | 7.63% | 7.58 | 9.29 | 1.22 | 1.07 |
| EOLS | Evolus, Inc. | $4.30 | 278.73M | +754% | +521% | — | — | -16.70 | 152.52 | 3.16 | -35.41 | — | -13.07 | 68.46% | -12.92% | -18.94% | 664.86% | -75.16% | -23.92% | 23.54 | -1.84 | 2.40 | 2.14 | -1.72 | -2500.00% | 3176.00% | -4536.00% | -2.31% | -0.29 | -42.53% | 0.00% | 0.00% | 2.46% | -25.72 | -45.46 | 3.32 | -0.33 |
| GALT | Galectin Therapeutics Inc… | $2.98 | 192.13M | — | — | — | — | -2.15 | -0.98 | — | -4.63 | -79.38 | -0.98 | 0.00% | — | — | 57.62% | 325.92% | -205.92% | -1.03 | -7.66 | 0.49 | 0.43 | -2.20 | 270.00% | — | 2670.00% | -41.38% | -1.18 | 320.80% | 0.09% | -0.20% | 0.09% | -4.53 | -4.60 | — | -40.88 |
| PRTC | PureTech Health plc | $16.77 | 405.3M | +112% | +57,154% | +51% | +506% | 17.42 | 1.17 | 100.26 | 3.72 | — | 1.17 | 26.04% | -2818.87% | 1108.33% | 6.32% | -117.31% | 4.29% | 0.05 | -13.56 | 9.33 | 9.19 | -6.91 | -18333.00% | 4498.00% | 2658.00% | -27.76% | -3.25 | -115.83% | 0.00% | 0.00% | 41.34% | -1.02 | -1.04 | 28.81 | 1.52 |
| QSI | Quantum-Si incorporated | $0.96 | 187.03M | +4,402% | -8% | — | — | -1.83 | 0.86 | 60.41 | 0.11 | -41.45 | 0.86 | 52.32% | -3550.56% | -3303.04% | -41.48% | -452.86% | -36.99% | 0.06 | — | 11.99 | 11.60 | 0.35 | 441.00% | 18262.00% | -698.00% | -50.01% | -4.83 | -385.30% | 0.00% | 0.00% | 0.00% | 0.11 | 0.13 | -3.90 | -0.42 |
| RCKT | Rocket Pharmaceuticals, I… | $5.01 | 542.19M | — | — | — | — | -2.48 | 1.99 | — | -2.38 | — | 2.59 | 0.00% | — | — | -60.27% | -135.95% | -52.00% | 0.09 | -122.55 | 6.38 | 2.57 | 0.25 | -2637.00% | — | -1166.00% | -34.48% | -6.29 | -111.72% | 0.00% | 0.00% | 0.00% | -2.16 | -2.62 | — | -1.60 |
| SLDB | Solid Biosciences Inc. | $6.21 | 483.82M | — | — | — | — | -1.77 | 1.61 | — | -0.79 | — | 1.61 | 0.00% | — | — | -94.57% | -623.56% | -70.53% | 0.18 | -381.55 | 5.20 | 4.92 | 0.46 | -3665.00% | — | 519.00% | -45.50% | -3.31 | -483.87% | 0.00% | 0.00% | 6.07% | -0.74 | -0.96 | — | -4.69 |
| SMLR | Semler Scientific, Inc. | $20.33 | 310.75M | +321% | +54% | +196% | — | 6.57 | 1.17 | 4.78 | 11.81 | 6.92 | 16.68 | 91.55% | 37.19% | 72.65% | 27.04% | 15.50% | 25.73% | 0.00 | — | 3.59 | 3.06 | -0.41 | 9506.00% | -1744.00% | 1881.00% | 9.06% | 3.87 | 21.12% | 0.00% | 0.00% | 0.00% | 12.13 | 10.43 | 4.51 | 18.96 |
| TCMD | Tactile Systems Technolog… | $29.29 | 657.24M | +114% | +65% | -58% | -43% | — | 3.06 | 2.03 | 16.77 | — | 4.51 | 75.17% | 8.89% | 5.79% | 0.00% | 11.72% | 0.00% | 0.07 | 28.21 | 4.03 | 3.11 | -1.88 | 1714.00% | 1247.00% | 599.00% | 6.03% | 1.05 | 26.58% | 0.00% | — | 6.69% | 20.58 | 14.90 | 1.83 | 9.68 |
| XOMA | XOMA Royalty Corp. | $25.53 | 316.14M | +157% | -39% | — | — | -18.47 | 3.12 | 8.96 | -49.66 | — | 4.56 | 99.28% | -140.33% | -48.52% | -16.20% | -36.44% | -6.07% | 1.46 | -2.89 | 5.15 | 5.01 | -3.24 | -5916.00% | 49872.00% | -2425.00% | -5.39% | -0.56 | -17.69% | 2.14% | -39.60% | 2.15% | -6.74 | -19.56 | 9.45 | -6.65 |
About Kamada Ltd.
Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. Further, it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis ; and ELIGARD for prostate cancer. The company markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Takeda Pharmaceuticals Company Limited; PARI GmbH; and Kedrion Biopharma. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.
- CEO
- Amir London
- Employees
- 420
- Beta
- 0.29
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($3.23 ÷ $8.21) − 1 = -60.66% (DCF, example).